

Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia

Monica Kasbekar,¹ Valentina Nardi,² Paola Dal Cin,³ Andrew M. Brunner,⁴ Meghan Burke,⁴ Yi-Bin Chen,⁵ Christine Connolly,⁴ Amir T. Fathi,⁴ Julia Foster,⁴ Molly Macrae,⁴ Steven L. McAfee,⁵ Kristin McGregor,⁶ Rupa Narayan,⁴ Aura Y. Ramos,⁴ Tina T. Som,⁴ Meghan Vartanian,⁴ Robb S. Friedman,⁶ Karim A. Benhadji,⁷ and Gabriela S. Hobbs⁴

¹Department of Medicine and ²Department of Pathology, Massachusetts General Hospital, Boston, MA; ³Department of Pathology, Brigham and Women's Hospital, Boston, MA; ⁴Massachusetts General Hospital Cancer Center, Boston, MA; ⁵Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA; ⁶Cancer Center, Newton-Wellesley Hospital, Newton, MA; and ⁷Taiho Oncology, Princeton, NJ

Key Points

- A novel *PCM1-FGFR1* gene rearrangement was identified in a patient with a myeloid neoplasm with eosinophilia.
- Futibatinib, an oral selective small molecule inhibitor of FGFR1-4, resulted in a durable complete hematologic and cytogenetic remission.

Introduction

The myeloid/lymphoid neoplasms with eosinophilia are a rare group of diseases defined by rearrangements of *PDGFRA*, *PDGFRB*, or *FGFR1* or by the fusion of *PCM1-JAK2*.^{1,2} Although neoplasms arising from rearrangements of *PDGFRA* and *PDGFRB* respond well to imatinib, those associated with *FGFR1* are typically aggressive and do not respond to imatinib or to other available tyrosine kinase inhibitors.¹ Therefore, allogeneic hematopoietic stem cell transplantation is recommended to achieve durable remissions.^{3,4} Here, we report the case of a patient with a novel fusion of *PCM1* with *FGFR1*, presenting as a myeloid neoplasm with eosinophilia, treated with an oral selective small molecule inhibitor of FGFR1-4 (futibatinib [TAS-120]) under a single-patient protocol, resulting in the first reported case of complete hematologic and cytogenetic remission using futibatinib in an FGFR1-driven myeloid neoplasm.


Case description

A 55-year-old male with a history of heart failure with preserved ejection fraction and chronic obstructive pulmonary disease presented with progressive dyspnea on exertion of a 3-weeks duration. Initial management included prednisone for a possible chronic obstructive pulmonary disease exacerbation and diuretics for possible volume overload. The dyspnea improved over time and was ultimately thought to be multifactorial. During the prednisone taper, peripheral blood eosinophilia was noted, with an absolute eosinophil count (AEC) of 3.6 K/ μ L. At that time, blood counts were as follows: white blood cell count, 16.64 K/ μ L (48% neutrophils, 9% lymphocytes, 10% monocytes, 22% eosinophils); hemoglobin, 13.8 g/dL; and platelets, 46 K/ μ L. Review of the peripheral smear demonstrated left-shifted myeloid elements, eosinophilia, and thrombocytopenia.

A bone marrow biopsy revealed a hypercellular (cellularity >95%) erythroid-dominant marrow with increased eosinophilic forms and increased pronormoblasts (Figure 1A-C). Flow cytometric analysis did not show evidence of a clonal B- or T-cell population or increased myeloblasts. A clinical next-generation sequencing (NGS) assay to detect common single-nucleotide variants and insertions/deletions in hematological malignancies (heme SNaPshot)⁵ did not show any abnormalities. Of note, this assay does not detect fusion proteins.

Break-apart fluorescence in situ hybridization (FISH) studies (performed at NeoGenomics Laboratories) revealed an *FGFR1* gene rearrangement in 11.3% of nuclei (normal <5.7%). The nature of the rearrangement was shown to be a paracentric inversion of chromosome 8p based on the distinct gap between the 5' *FGFR1* and 3' *FGFR1* probes seen in 12 of 20 metaphases on FISH (Figure 2B-C; performed at Brigham and Women's Hospital Cytogenetics Laboratory). A targeted NGS assay for fusion transcript detection (heme fusion assay)⁵ revealed a *PCM1-FGFR1* fusion transcript (40 unique fusion reads). The rearrangement was consistent with an in-frame fusion of *PCM1* (exons 1-36) to

Figure 1. Bone marrow specimens before and after treatment with futibatinib. (A-C) Before futibatinib treatment. (A) Hematoxylin and eosin staining reveals hypercellular bone marrow (cellularity approximately >95%) (original magnification $\times 10$). (B) A higher-magnification image of panel A shows complete myeloid maturation with increased eosinophilic forms (original magnification $\times 100$). (C) Clusters of immature cells, most consistent with immature erythroid elements, account for $\sim 25\%$ of bone marrow cellularity (original magnification $\times 40$). (D-E) After futibatinib treatment. (D) Hematoxylin and eosin staining of the bone marrow core shows decreased marrow cellularity ($\sim 20\%$) (original magnification $\times 20$). (E) A higher-magnification image shows maturing trilineage hematopoiesis, without evidence of increased eosinophilic forms or increased pronormoblasts (original magnification $\times 40$).



FGFR1 (exons 11-18) (Figure 2A). Taken together, the findings established a diagnosis of a myeloid neoplasm with eosinophilia driven by rearrangement of *FGFR1*.

The patient was initially treated with prednisone, and the AEC was noted to decrease to 0.03 K/ μ L and subsequently fluctuate between 0.20 K/ μ L and 2.72 K/ μ L. He was also evaluated for hematopoietic stem cell transplantation; however, he was not a candidate because of comorbidities. Given the presence of the *FGFR1* fusion transcript and the lack of an adequate steroid-sparing therapy, he enrolled (with informed consent) on a single-patient protocol in an expanded-access program for the selective FGFR inhibitor futibatinib (TAS-120; Taiho Oncology).

The patient started on oral futibatinib (20 mg/d); 7 days after initiation of therapy, elimination of peripheral eosinophilia was noted (AEC, 0.03 K/ μ L). Prednisone was discontinued within 1 month without recurrence of eosinophilia.

After 7 days of treatment with futibatinib, hyperphosphatemia, a common side effect of FGFR inhibition thought to be related to FGF23 signaling, developed (5.3 mg/dL).⁶ Sevelamer was started, with normalization of phosphorus levels. After 2 months of therapy, the patient reported grade 1 dry pruritic skin on his face and ears by Common Terminology Criteria for Adverse Events v.5.0. After 3 months, he developed a bullous rash on his arms and legs (grade 2), prompting drug interruption for 7 days (days 93-99). The rash resolved, and he was reinitiated on the drug with a 20% dose reduction (16 mg/d).

On day 175 of therapy, repeat bone marrow biopsy showed a moderately hypocellular marrow with maturing trilineage hematopoiesis and no pronormoblasts (Figure 1D-E). Blood counts showed white blood cell count, 5.0 K/ μ L (67% neutrophils, 21% lymphocytes, 9.6% monocytes, 1.4% eosinophils); hemoglobin, 13.2 g/dL; and platelets, 119 K/ μ L. The *PCM1-FGFR1* fusion transcript was no longer detectable by heme fusion assay. Furthermore, the paracentric inversion of chromosome 8 was no longer observed on metaphase FISH (20 metaphases tested), consistent with cytogenetic remission. The patient continues on futibatinib, with ongoing evidence of hematologic and cytogenetic remission after >18 months of therapy.

Methods

Molecular testing

Two clinically validated NGS assays (heme SNaPshot and heme fusion) were used.⁵ The heme SNaPshot assay detects single-nucleotide variants and insertions/deletions in 103 gene targets commonly mutated in hematological malignancies. The heme fusion assay detects gene rearrangements in 89 commonly rearranged genes in hematologic malignancies. Briefly, genomic DNA (heme SNaPshot) or total nucleic acid (heme fusion) was isolated from bone marrow aspirates using standard protocols. Sequencing was performed with Illumina NextSeq using a validated anchored multiplex polymerase chain reaction assay.⁵

The patient enrolled in this study under an expanded-access program. The single-patient Investigational New Drug Application




Figure 2. Fusion of *PCM1* to *FGFR1* as the genetic driver for this myeloid neoplasm with eosinophilia. (A) Illustration of the in-frame fusion of *PCM1* (exons 1-36) to *FGFR1* (exons 11-18), resulting in amino acid 1947 of *PCM1* juxtaposed to amino acid 429 of *FGFR1*. The coiled-coil motifs (blue, shown with corresponding amino acid numbers) of *PCM1* are thought to drive dimerization of the *FGFR1* tyrosine kinase domain (red, shown with corresponding amino acid numbers). (B) Partial GTG banded karyotype demonstrating both chromosomes 8. The normal chromosome (left) and the abnormal chromosome with a distinctly abnormal 8p region pattern caused by *inv(8)(p11.2p22)* (right). (C) Corresponding partial metaphase FISH karyotype using a home-brew break-apart *FGFR1* probe set. A distinct gap between the 5' *FGFR1* centromeric (green) probe and the 3' *FGFR1* telomeric (red) probe is clearly observed on the abnormal chromosome 8 (right), consistent with paracentric inversion between the 8p11 and 8p22 bands.

was submitted and approved by the Massachusetts General Hospital Institutional Review Board.

Karyotyping and FISH evaluation

Initial break-apart interphase FISH studies using bone marrow specimens were performed and interpreted at NeoGenomics Laboratories. Subsequent testing was performed at Brigham and Women's Cyto genetics Laboratory, where GTG-banded metaphases were obtained from unstimulated bone marrow cultures, according to standard cytogenetic protocols. Metaphase FISH testing for *FGFR1* rearrangement was performed according to standard protocols, with a break-apart *FGFR1* probe set, specific for the 5' and 3' regions of *FGFR1*.

Results and discussion

Our patient presented with a myeloid neoplasm driven by an *FGFR1* rearrangement, a rare and aggressive hematologic malignancy that is often accompanied by eosinophilia.⁷⁻⁹

A novel gene rearrangement, resulting in *PCM1-FGFR1* fusion, was identified as the putative genetic driver of disease in this case. Similar to other fusion-driven neoplasms, no other clonal marker was identified, suggesting that the single-fusion event is sufficient to cause disease. Fewer than 20 *FGFR1* fusion partners have been described,¹⁰⁻¹² with *ZMYM2* and *BCR* being the most commonly observed.¹³ Although the fusion of *PCM1* and *FGFR1* has yet to be reported, *PCM1* has been implicated in the pathogenesis of other myeloid/lymphoid neoplasms.¹⁴ Specifically, the *PCM1-JAK2* rearrangement was added as a provisional entity in the 2016 World Health Organization classification of myeloid/lymphoid neoplasms with eosinophilia. A single case of a *PCM1-PDGFRB* fusion has

also been reported.¹⁵ As with these analogous fusion proteins, the *PCM1-FGFR1* fusion is expected to result in ligand-independent constitutive activation of *FGFR1*, with the coiled-coil motifs of *PCM1* driving dimerization of the tyrosine kinase.¹⁶

The role of the *FGFR1* fusion partner in driving constitutive activation of the tyrosine kinase is of clear importance in disease pathogenesis; however, little is known about the impact of different fusion partners on disease biology and clinical presentation. Importantly, there is evidence to suggest that different *FGFR1* fusion partners result in varying clinical manifestations of disease. For example, the *ZNF198-FGFR1* fusion and the *BCR-FGFR1* fusion have been shown to induce distinct phenotypes via different signaling pathways in a mouse model.¹⁷

Given that this is the first report of a *PCM1* and *FGFR1* fusion, the specific effect of *PCM1* in this patient's disease is unclear; however, features of the *PCM1-JAK2* rearrangement provide hypotheses. Notably, the *PCM1-JAK2* rearrangement has been associated with large aggregates of immature erythroid precursors on bone marrow biopsy.¹⁸ Interestingly, evaluation of our patient's bone marrow revealed an unusual and striking increase in immature erythroid elements, with 25% pronormoblasts; it is possible that this observation is an effect of *PCM1*. Nevertheless, it is currently unknown how the identity of the *FGFR1* fusion partner may affect clinical response to therapies; as such, treatment of these myeloid/lymphoid neoplasms is guided by the identification of an *FGFR1* rearrangement by karyotype and FISH.

In our case, the identification of the *FGFR1* rearrangement suggested that selective tyrosine kinase inhibition would be a viable treatment strategy.^{19,20} Therefore, we treated our patient with

futibatinib, a potent second-generation irreversible inhibitor of FGFR1-4 that has been used in the treatment of cholangiocarcinoma driven by *FGFR2* gene fusions and rearrangements.^{21,22} With futibatinib, our patient achieved and maintained hematologic and cytogenetic remission. These observations share similarities with a recent case report demonstrating complete remission of a myeloid/lymphoid neoplasm with eosinophilia using an FGFR inhibitor; however, in that case, the neoplasm was driven by a *CEP110-FGFR1* rearrangement, and treatment involved pemigatinib, an inhibitor of FGFR1/2/3.²³

To our knowledge, this case represents the first use of futibatinib to achieve a durable hematologic and cytogenetic remission in a patient with a myeloid neoplasm and *FGFR1* rearrangement. Hematologic malignancies driven by *FGFR1* rearrangement are aggressive and, historically, have been unresponsive to chemotherapeutic regimens. Just as imatinib revolutionized the treatment of *BCR-ABL*-driven chronic myelogenous leukemia, the use of new selective tyrosine kinase inhibitors has the potential to dramatically affect outcomes in patients with *FGFR1*-driven neoplasms. Our findings support the use of these inhibitors as a therapeutic strategy, and ongoing clinical trials may establish the utility of FGFR inhibitors as first-line therapy for patients with myeloid/lymphoid neoplasms with *FGFR1* rearrangement.

Acknowledgments

The authors thank the patient described in this report, the entire research staff at the Massachusetts General Hospital for helping him to receive this treatment, and Taiho Oncology.

References

- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [published correction appears in *Blood*. 2016;128(3):462-463]. *Blood*. 2016;127(20):2391-2405.
- Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. *Blood*. 2017;129(6):704-714.
- Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. *Acta Haematol*. 2002;107(2):101-107.
- Bain BJ. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. *Haematologica*. 2010;95(5):696-698.
- Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. *Nat Med*. 2014;20(12):1479-1484.
- Chae YK, Ranganath K, Hammerman PS, et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. *Oncotarget*. 2017;8(9):16052-16074.
- Boyer DF. Blood and bone marrow evaluation for eosinophilia. *Arch Pathol Lab Med*. 2016;140(10):1060-1067.
- Valent P. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. *Blood Rev*. 2009;23(4):157-165.
- Akuthota P, Weller PF. Spectrum of eosinophilic end-organ manifestations. *Immunol Allergy Clin North Am*. 2015;35(3):403-411.
- Savage N, George TI, Gotlib J. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review. *Int J Lab Hematol*. 2013;35(5):491-500.
- Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. *Hum Pathol*. 2010;41(4):461-476.
- Sohal J, Chase A, Mould S, et al. Identification of four new translocations involving FGFR1 in myeloid disorders. *Genes Chromosomes Cancer*. 2001;32(2):155-163.
- Strati P, Tang G, Duose DY, et al. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. *Leuk Lymphoma*. 2018;59(7):1672-1676.
- Patterer V, Schnittger S, Kern W, Haferlach T, Haferlach C. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. *Ann Hematol*. 2013;92(6):759-769.
- Ghazzawi M, Mehra V, Knut M, et al. A novel PCM1-PDGFRB fusion in a patient with a chronic myeloproliferative neoplasm and an ins(8;5). *Acta Haematol*. 2017;138(4):198-200.
- Murati A, Gelsi-Boyer V, Adélaïde J, et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. *Leukemia*. 2005;19(9):1692-1696.

Authorship

Contribution: M.K. and G.S.H. wrote the manuscript; G.S.H. developed the treatment concept and wrote the clinical trial; V.N. and P.D.C. edited the manuscript and assisted with methods and figures; and A.M.B., M.B., Y.-B.C., C.C., A.T.F., J.F., M.M., S.L.M., K.M., R.N., A.Y.R., T.T.S., M.V., R.S.F., and K.A.B. edited the manuscript.

Conflict-of-interest disclosure: A.M.B. is on the scientific advisory board for Celgene, Jazz Pharmaceuticals, and Forty Seven Inc.; and receives research funding from AstraZeneca, Celgene, and Novartis. Y.-B.C. has acted as a consultant for Takeda, Incyte, Magenta, AbbVie, Daiichi, and Equillium. A.T.F. has acted as a consultant for Celgene, Takeda, Astellas, AbbVie, Amgen, and Daiichi Sankyo; has been a member of advisory boards for Pfizer, Tolero Pharmaceuticals, and AbbVie; and has received clinical trial support from Celgene and Agios. R.N.'s spouse is employed by Takeda and has equity in Takeda and Genentech. K.A.B. is employed by Taiho Oncology and is a stock holder in Eli Lilly. G.S.H. is on the scientific advisory board for Jazz Pharmaceuticals, Agios, Incyte, Merck, and Celgene and receives research funding from the K-12 Paul Calabresi Award, the American Society of Hematology-Harold Amos Faculty Development Award Program, and the Sanchez Ferguson Research Award. The remaining authors declare no competing financial interests.

ORCID profile: G.S.H., 0000-0002-0199-9333.

Correspondence: Gabriela S. Hobbs, Massachusetts General Hospital Cancer Center, Zero Emerson Pl, Office 138, Boston, MA 02114; e-mail: ghobbs@partners.org.

17. Roumiantsev S, Krause DS, Neumann CA, et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. *Cancer Cell*. 2004;5(3):287-298.
18. Tang G, Sydney Sir Philip JK, Weinberg O, et al. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. *Mod Pathol*. 2019; 32(4):490-498.
19. Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. *Cancer Res*. 2012;72(8):2045-2056.
20. Gozgit JM, Wong MJ, Moran L, et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. *Mol Cancer Ther*. 2012;11(3):690-699.
21. Meric-Bernstam F, Arkenau H, Tran B, et al. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. *Ann Oncol*. 2018;29(suppl 5): v100-v110.
22. Touat M, Ileana E, Postel-Vinay S, André F, Soria JC. Targeting FGFR signaling in cancer. *Clin Cancer Res*. 2015;21(12):2684-2694.
23. Verstovsek S, Subbiah V, Masarova L, et al. Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor. *Ann Oncol*. 2018;29(8):1880-1882.